Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 3:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 21,191 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Immunity Disorders Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Immune Response to Different Combinations of the DNA-HIV-PT123 and AIDSVAX® B/E Vaccines in Healthy, HIV-Uninfected Adults

NCT02207920
View directory record Official record
Conditions
HIV Infections
Interventions
AIDSVAX B/E Vaccine, DNA-HIV-PT123 Vaccine, Placebo for DNA-HIV-PT123, Placebo for AIDSVAX B/E
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
7
States / cities
San Francisco, California • New York, New York • Rochester, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2021 · Synced Oct 20, 2026, 3:24 AM EDT
Recruiting Phase 3 Interventional

Clinical Application of Stem Cell Educator Therapy in Type 1 Diabetes

NCT04011020
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Stem Cell Educator therapy
Combination Product
Lead sponsor
Throne Biotechnologies Inc.
Industry
Eligibility
10 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Paramus, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 20, 2026, 3:24 AM EDT
Terminated Not applicable Interventional

Donor Stem Cell Transplant Followed By Donor White Blood Cell Infusions in Treating Young Patients With Hematologic Cancer

NCT00301860
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
anti-thymocyte globulin, filgrastim, therapeutic allogeneic lymphocytes, cyclosporine, fludarabine phosphate, melphalan, methotrexate, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
Up to 21 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 15, 2013 · Synced Oct 20, 2026, 3:24 AM EDT
Active, not recruiting Phase 3 Interventional

Study of Immune Globulin Intravenous (Human) GC5107 in Pediatric Subjects With Primary Humoral Immunodeficiency

NCT04565015
View directory record Official record
Conditions
Primary Immune Deficiency
Interventions
GC5107
Biological
Lead sponsor
GC Biopharma Corp
Industry
Eligibility
2 Years to 16 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
5
States / cities
Aurora, Colorado • Centennial, Colorado • Dallas, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2025 · Synced Oct 20, 2026, 3:24 AM EDT
Completed No phase listed Observational

HIV-HCV Coinfection: Impact of Immune Dysfunction

NCT00575315
View directory record Official record
Conditions
HIV Infections, Hepatitis
Interventions
Not listed
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 90 Years
Enrollment
634 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 20, 2014 · Synced Oct 20, 2026, 3:24 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived HIV-1 Recombinant Envelope Glycoprotein (gp160)

NCT00000968
View directory record Official record
Conditions
HIV Infections
Interventions
gp160 Vaccine (Immuno-AG)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 1993
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 20, 2026, 3:24 AM EDT
Recruiting Phase 4 Interventional

Immune Modulation During Palynziq® Treatment in Adults (IMPALA)

NCT07477691
View directory record Official record
Conditions
Phenylketonuria
Interventions
Pegvaliase, Methotrexate
Biological · Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
12
States / cities
Los Angeles, California • Aurora, Colorado • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 20, 2026, 3:24 AM EDT
Recruiting Phase 4 Interventional

Menopausal HT for Women Living With HIV (HoT)

NCT06856174
View directory record Official record
Conditions
HIV Infection, Menopause
Interventions
Transdermal estradiol gel, Micronized Progesterone, Placebo for estradiol gel, Placebo for micronized progesterone
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
40 Years to 60 Years · Female only
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
23
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 18 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 20, 2026, 3:24 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Oxaliplatin, Fludarabine, Cytarabine and Rituximab in Richter's Syndrome, Refractory CLL and PLL

NCT00452374
View directory record Official record
Conditions
Leukemia
Interventions
Cytarabine, Fludarabine, Oxaliplatin, Rituximab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
2
States / cities
La Jolla, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 2, 2011 · Synced Oct 20, 2026, 3:24 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Tolerability and Pharmacokinetics of Oral Doses of SAR442168 With a Food Effect Investigation in Healthy Adult Participants

NCT06106074
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Tolebrutinib, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 45 Years
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 30, 2023 · Synced Oct 20, 2026, 3:24 AM EDT
Completed Phase 3 Interventional

Combination Chemotherapy in Treating Pediatric Patients With Advanced-Stage Large Cell Lymphoma

NCT00002618
View directory record Official record
Conditions
Lymphoma
Interventions
filgrastim, cytarabine, doxorubicin hydrochloride, leucovorin calcium, mercaptopurine, methotrexate, prednisone, vincristine sulfate, low-LET cobalt-60 gamma ray therapy, low-LET electron therapy, low-LET photon therapy
Biological · Drug · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2006
U.S. locations
8
States / cities
Wichita, Kansas • New Orleans, Louisiana • Asheville, North Carolina + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2014 · Synced Oct 20, 2026, 3:24 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Characterizing Late-season Influenza Vaccine Responses to Compare the 2023 and 2024 Vaccine Formulations

NCT06567860
View directory record Official record
Conditions
Influenza A
Interventions
Influenza Fluzone vaccine
Biological
Lead sponsor
La Jolla Institute for Immunology
Other
Eligibility
18 Years to 64 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 20, 2026, 3:24 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment

NCT02932280
View directory record Official record
Conditions
Solid Tumor, Central Nervous System Tumor, Lymphoma, Leukemia
Interventions
Neratinib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
3 Years to 21 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
8
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Palo Alto, California + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2025 · Synced Oct 20, 2026, 3:24 AM EDT
Completed No phase listed Observational

Interventions to Decrease the Risk of Mother-to-Child Transmission of HIV in India

NCT00341796
View directory record Official record
Conditions
HIV-1
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
Female only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 20, 2026, 3:24 AM EDT
Terminated Phase 2 Interventional Results available

Lenalidomide and Nivolumab in Treating Patients With Relapsed or Refractory Multiple Myeloma

NCT03333746
View directory record Official record
Conditions
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions
Laboratory Biomarker Analysis, Lenalidomide, Nivolumab, Pharmacological Study
Other · Drug · Biological
Lead sponsor
Yvonne Efebera
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 30, 2019 · Synced Oct 20, 2026, 3:24 AM EDT
Completed Phase 1 Interventional

Comparison of Dendritic Cell-Based Therapeutic Vaccine Strategies for HIV Functional Cure

NCT03758625
View directory record Official record
Conditions
HIV Infections
Interventions
a1DC + inactivated whole autologous HIV, a1DC + conserved HIV peptides, a1DC + no antigen, pgDC + inactivated whole autologous HIV, pgDC + conserved HIV peptides, pgDC + no antigen
Biological
Lead sponsor
Sharon Riddler
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
2
States / cities
Columbus, Ohio • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Oct 20, 2026, 3:24 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Identification of β Cell Dysfunction in Relatives of Individuals With Type 1 Diabetes Mellitus

NCT04362917
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
There is no intervention
Other
Lead sponsor
Indiana University
Other
Eligibility
12 Years to 55 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 16, 2023 · Synced Oct 20, 2026, 3:24 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL

NCT02972840
View directory record Official record
Conditions
Lymphoma, Mantle Cell
Interventions
Acalabrutinib, Bendamustine, Rituximab, Placebo
Drug
Lead sponsor
Acerta Pharma BV
Industry
Eligibility
65 Years and older
Enrollment
635 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
32
States / cities
Tucson, Arizona • Downey, California • Santa Monica, California + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 20, 2026, 3:24 AM EDT
Completed Phase 1 Interventional

In Vitro Basophil Responsiveness to Allergen Challenge After Gamma-tocopherol Supplementation in Allergic Asthmatics

NCT00836368
View directory record Official record
Conditions
Allergic, Asthmatic, Allergy, Asthma
Interventions
gamma-tocopherol
Dietary Supplement
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 50 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 7, 2011 · Synced Oct 20, 2026, 3:24 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Development and Evaluation of A Mailed Arthritis Self-Management Program

NCT00448474
View directory record Official record
Conditions
Osteoarthritis, Rheumatoid Arthritis
Interventions
Mailed Arthritis Self-Management Education
Behavioral
Lead sponsor
University of North Carolina
Other
Eligibility
18 Years and older
Enrollment
900 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 16, 2007 · Synced Oct 20, 2026, 3:24 AM EDT
Completed Phase 2 Interventional Results available

Phase II/III Study Evaluating the Effect of IL-2 on Preservation of the CD4 T-Lymphocytes After Interruption of Antiretroviral Treatment in HIV-Infected Patients With CD4 T-Lymphocyte Count Greater Than 500 Cells/mm3 Who Received Antiretroviral Tx

NCT00071890
View directory record Official record
Conditions
HIV Infections
Interventions
Interleukin 2, HAART, Treatment interruption
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 5, 2010 · Synced Oct 20, 2026, 3:24 AM EDT
Completed Not applicable Interventional Results available

Erwinase Study in Patients With Acute Lymphoblastic Leukemia

NCT00506597
View directory record Official record
Conditions
Leukemia
Interventions
Erwinase
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 11, 2014 · Synced Oct 20, 2026, 3:24 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of GSK Biologicals HIV Vaccine in Antiretroviral Therapy (ART)-naïve HIV-1 Infected Persons

NCT01218113
View directory record Official record
Conditions
AIDS
Interventions
GSK Biologicals HIV Vaccine 732462, Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
17
States / cities
Bakersfield, California • Long Beach, California • Washington D.C., District of Columbia + 13 more
Source: ClinicalTrials.gov public record
Updated May 21, 2018 · Synced Oct 20, 2026, 3:24 AM EDT
Recruiting Phase 2 Interventional

Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL

NCT05952024
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma
Interventions
Acalabrutinib, Rituximab
Drug · Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
65 Years to 99 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
14
States / cities
Berkeley, California • La Jolla, California • Orange, California + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 20, 2026, 3:24 AM EDT